Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by Gustoeson Feb 11, 2015 9:21am

134 Views

Post# 23417400

Theralase Ranked in 2015 Toronto Stock Exchange Venture 50®

(via Thenewswire.ca)

Toronto, Ontario / TheNewswire / February 11, 2015 /Theralase Technologies Inc. ("Theralase")(TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that it has been ranked in the Toronto Stock Exchange Venture ("TSXV") 50(R).

Every year, the TSX Venture 50(R) ranks the strongest companies on the TSXV by share price, trading volume, market capitalization and analyst coverage. The winning companies have seen impressive growth over the past year, offered strong return to their shareholders and are actively traded in the market.

The TSX Venture 50(R) are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and clean technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2014.

The ranking is being announced today with the TSXV's official news release that will reach print, online and broadcast media across Canada and around the world. An additional communication will be sent to analysts and brokers, encompassing broad distribution to the Canadian investment industry. In addition, banner ads will be placed on two key Canadian business sites with high traffic volume; specifically: www.TMX.com , www.TMXmoney.com and finally linking to a dedicated microsite: www.TMX.com/Venture50

Roger Dumoulin-White, President and CEO of Theralase stated that, "On behalf of Theralase, I am honoured to accept the award of being ranked in the prestigious TSX Venture 50(R). The TSX Venture 50(R) represents the cream of the crop of public companies that have shown the commitment to build long term shareholder value through the execution and realization of strategic objectives. In 2015, Theralase will execute on two strategic objectives aimed at increasing long term shareholder value in both our Therapeutic Laser Technology ("TLT") and Photo Dynamic Therapy ("PDT") divisions; specifically: the launch of our next generation TLC-2000 therapeutic laser with Cell SensingTM technology that provides higher efficacy than any other therapeutic laser on the market and the commencement of our Health Canada / FDA Phase I / II a clinical trial in humans for Non Muscle Invasive Bladder Cancer ("NMIBC") aimed at the destruction of bladder cancer."